Diagnostic tests created by Cypress, Calif.-based Focus Diagnostics and Hamburg, Germany-based Altona Diagnostics have already been authorized for emergency use by the FDA.
While Hologic’s Aptima Zika Virus test is not approved by the FDA, the agency says it may be used as long as Zika is still considered a public health emergency.
The FDA intends for the authorization of this third diagnostic test to expand the number of labs that can test for Zika. The test will be available for use in all 50 states, U.S. territories and Puerto Rico.
After news of the authorization, Hologic’s stock rose 1.75 percent to $34.40 a share, boosting the company’s market valuation by almost $165 million.
More articles on supply chain:
FDA finalizes symbols for device labels
FDA approves Lannett’s antibiotic
Boston Scientific tacks on new warnings to controversial surgical mesh devices
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
